• Endothelial secretion of von Willebrand factor (VWF) promotes inflammation and thrombosis.
Summary. Background: Aberrant secretion of von Willebrand factor (VWF) from endothelial cells contributes to inflammation and vascular thrombosis. Agonist-induced VWF secretion is facilitated by protein kinase and phosphatase-mediated signaling. Although the catalytic subunit of protein phosphatase 2B (PP2B-Aa) is targeted to the secretory machinery via an interaction with the vesicle trafficking protein Munc18c in endothelial cells, the functional relevance of this phosphatase complex is unclear. Objective: To assess the contribution of the PP2B-Aa-Munc18c complex to endothelial VWF secretion. Results: Here, we show that amino acids 120-130 of PP2B-Aa are important to support an interaction with Munc18c. A synthetic myristylated cell-permeable peptide, which is derived from amino acids 121-130 of PP2B-
Introduction
Endothelial cells (ECs) rapidly trigger the secretion of hemostatic and inflammatory modulators, including von Willebrand factor (VWF), from Weibel-Palade bodies following vascular perturbation. Augmented plasma levels of VWF are associated with an increased risk of arterial thrombosis in coronary heart disease, stroke, and venous thromboembolism [1] [2] [3] . Genetic variations in the vesicular trafficking proteins are associated with alterations in VWF concentration and activity, and the risk of arterial thrombosis [4, 5] , suggesting a physiologic role for EC secretion.
An essential step in VWF secretion is the fusion of Weibel-Palade bodies with the plasma membrane, and is mediated in part, by soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins. Secretion occurs through a core complex that is formed between the target SNAREs (syntaxin-4 and SNAP-23) on the membrane, and vesicle SNARE (vesicle-associated membrane protein-3) on the Weibel-Palade bodies [6] [7] [8] [9] . Endothelial SNARE complex formation is further regulated by additional accessory proteins, including Munc18c. Munc18c suppresses secretion by interacting with the target SNARE syntaxin-4, and thus sequestering syntaxin-4, preventing it from becoming a part of the multimeric core complex [7] . Post-translational modification such as tyrosine or serine phosphorylation of Munc18c promotes dissociation of Munc18c from syntaxin-4, and facilitates secretion [7, 10, 11] .
Although several studies on the secretion of endothelial contents have focused on the phosphorylation events mediated by protein kinases [7, 12, 13] , we previously reported that genetic and pharmacologic inhibition of protein phosphatase 2B (PP2B) (also referred to as calcineurin or protein phosphatase 3) enhanced VWF secretion [14] . PP2B is a Ca 2+ and calmodulin-activated enzyme, and exists as a heterodimer of a catalytic subunit (PP2B-A; CNA) and a regulatory subunit (PP2B-B; CNB). The catalytic subunit has three isoforms: PP2B-Aa and PP2B-Ab (ubiquitous), and PP2B-Ac (testis) [15, 16] .
In our previous study, an interaction of PP2B-Aa with Munc18c was noticed [14] , but the functional relevance of the PP2B-Aa-Munc18c complex remained unexplored. The aim of this study was to understand the specific contribution of PP2B-Aa-Munc18c to endothelial physiology as it relates to secretion. Here, we mapped the binding site of Munc18c on the PP2B-a subunit, and utilized this information to generate a cell-permeable synthetic peptide. This novel reagent disrupted PP2B-Aa-Munc18c in ECs, and blocked agonist-induced VWF exocytosis.
Materials and methods

ECs
Human umbilical cord vein ECs (HUVECs) were obtained as previously described, with minor modifications [14] . Briefly, umbilical cord veins were washed with phosphate-buffered saline (PBS) and subjected to collagenase digestion. The resultant HUVECs were seeded onto T-25 culture flasks and maintained in endothelial basal medium EBM-Plus (Lonza, Walkersville, MD, USA). All of the cells used in this study were from passages 1-4.
Generation of glutathione-S-transferase (GST)-tagged C-terminal truncation mutants of PP2B-Aa proteins PPP3CA with a truncation at amino acid 347 and tagged to GST at the N-terminus in the pGEX-6P plasmid was obtained from A. Rao (Harvard Medical School, Boston, MA, USA). By introducing a stop codon through sitedirected mutagenesis, we generated additional C-terminal PP2B-Aa mutants with truncations at amino acids 100, 110, 120, 125, 130, 140, 150, 171, 200, and 300. Amino acids selected for truncation were predicted not to affect the overall secondary structure of PP2B-Aa, based on the YASPIN secondary structure prediction website from the Center for Integrative Bioinformatics VU (IBIVU, Amsterdam, the Netherlands). GST-tagged proteins were expressed in Escherichia coli after isopropyl-b-D-thiogalactopyranoside induction, and purified by the use of glutathione beads (GE Healthcare, Amersham, UK). Proteins were dialyzed against PBS after elution, and characterized by Coomassie Blue staining.
GST pulldown assays
HUVECs were lysed with Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA, USA), which contains 1% Triton. Lysate (500 lg) was mixed with GST and truncated GST-PP2B-Aa proteins (10 lg) for 1 h at 4°C, following which glutathione beads were added and incubated for an additional 1 h. Beads were washed three times, and analyzed on a 10% SDS-PAGE gel; this was followed by immunoblotting with anti-Munc18c (Abcam, Cambridge, MA, USA) antibody.
Coimmunoprecipitation assays and western blots
HUVECs were pretreated with dimethylsulfoxide (DMSO) vehicle (0.08%), 10 lM scrambled control myristylated peptide (Myr-FDIVYECGSR) or 10 lM PP2B myristylated peptide (Myr-121 DRGYFSIECV 130 ) (Peptide 2.0, Chantilly, VA, USA) for 30 min. HUVECs were washed with PBS, and the cells were lysed with RIPA Buffer (Cell Signaling Technology) containing 1% NP-40. Lysate (800 lg) was immunoprecipitated with 3 lg of anti-PP2B-Aa (Bethyl Laboratories, Montgomery, TX, USA) and rabbit IgG antibodies. The antibody complex was captured with protein A sepharose beads. Proteins bound to the beads were washed with RIPA buffer, and separated on an SDS-PAGE gel. Gels were transferred to the nitrocellulose membrane, and immunoblotted with anti-Munc18c antibody. The blot was stripped and reprobed with anti-PP2B-Aa antibody. HUVECs pretreated with peptides and challenged with histamine (10 lM) were lysed in RIPA buffer, and 40 lg of protein was separated on an SDS-PAGE gel. Gels transferred to the membrane were immunoblotted with anti-phosphoSer95 SNAP-23 [17] and SNAP-23 (Affinity Bioreagents Golden, CO, USA) antibodies.
VWF secretion assays
HUVECs pretreated with DMSO, scrambled peptides and PP2B peptides as described above were then challenged with histamine (5 lM or 10 lM) or thrombin (0.05 U mL À1 or 0.5 U mL À1 ) for an additional 30 min.
Cells without any agonist treatment served as a control.
In some studies, cells were treated with 5 mM H 2 O 2 , which blocks VWF secretion by inhibiting N-ethylmaleimide-sensitive factor (NSF) [18] . In some experiments, scrambled and PP2B peptides were added 30 min after histamine treatment and incubated for an additional 1 h.
The VWF antigen level in cell supernatants was analyzed with a standard ELISA technique. Samples were incubated for 2 h on microtiter plates precoated with 1 lg mL À1 rabbit anti-human VWF antibody (Dako, Carpinteria, CA, USA). After several washes, samples were incubated with 2 lg mL À1 horseradish peroxidaseconjugated anti-human VWF antibody (Dako), and color-developed with the addition of 3,3 0 ,5,5 0 -tetramethylbenzidine (Thermo Fisher Scientific, Waltham, MA, USA). The reaction was stopped with 1 M HCl, and the absorbance was read at 450 nm. Absorbance was converted to percentage of plasma VWF by comparing the absorbance values with a standard curve generated from human plasma samples. Fold differences in VWF antigen levels were determined after normalizing the VWF values obtained for test samples (peptide and/or agonist treatment) to those obtained from media wherein cells were left untreated.
Statistics
The statistical significance of the data was analyzed with a two-tailed unpaired Student's t-test. Data are expressed as mean AE standard error of the mean, and P < 0.05 was considered to be significant.
Results and discussion
To map the binding site of Munc18c on PP2B-Aa, we generated various C-terminal truncation mutants of GST-PP2B-Aa (Fig. 1A) and performed pulldown assays. As GST-PP2B-Aa truncated at amino acid 347 could interact with Munc18c [14] , additional GST-PP2B-Aa proteins truncated at amino acids 300, 200 and 100 were generated and characterized by Coomassie Blue staining (Fig. 1B, lower panel) . In a GST pulldown assay, Munc18c interacted with GST-PP2B-Aa mutants 300 and 200. In contrast, GST-PP2B-Aa mutant 100 and the control GST did not support Munc18c binding (Fig. 1B,  upper panel) . These studies indicate that the binding site of Munc18c on PP2B-Aa may reside between amino acids 100 and 200. To further map the minimal region that supports Munc18c interaction, we generated additional GST-PP2B-Aa mutants truncated at amino acids 125, 150 and 171 (Fig. 1C, lower panel) . Pulldown assays revealed that Munc18c interacted with GST-PP2B-Aa mutants 171 and 150 but only weakly with GST-PP2B-Aa mutant 125. No interaction was noted with GST protein (Fig. 1C, upper panel) . These studies suggest that the interaction site of Munc18c in PP2B-Aa is probably between amino acids 100 and 150. Finally, fine mapping was performed with additional PP2B-Aa mutants truncated at amino acids 110, 120, 130, 140 and 150 (Fig. 1D , lower panel). GST pulldown assays showed that Munc18c interacted with GST-PP2B-Aa mutants 150 and 130, and weakly with GST-PP2B-Aa mutant 140. Importantly, Munc18c failed to interact with GST-PP2B-Aa mutants 120, 110 and 100 (Fig. 1D, upper panel) . Collectively, these studies indicate that amino acids 120-130 on PP2B-Aa may be important to support Munc18c binding. On the basis of the mapping studies, we generated a synthetic myristylated PP2B cell-permeable peptide (Myr-121 DRGYFSIECV 130 ), which is derived from amino acids 121-130 in PP2B-Aa along with a scrambled control peptide. We investigated whether the PP2B peptide was capable of disrupting endogenous PP2B-Aa-Μunc18c, by using coimmunoprecipitation studies. Munc18c was detected in PP2B-Aa immunoprecipitates obtained from DMSO-treated and scrambled peptidetreated HUVECs. Treatment of HUVECs with the PP2B peptide moderately disrupted the interaction of Munc18c with PP2B-Aa ( Fig. 2A) . In an alternative approach, Munc18c from DMSO-treated and scrambled peptidetreated HUVECs interacted with GST-PP2B-Aa 200 in a pulldown assay. Disruption of PP2B-Aa-Munc18c complexes was evident when lysate from the PP2B peptide-treated HUVECs was used (Fig. 2B) . These studies indicate that the myristylated PP2B peptide disrupts endogenous PP2B-Aa-Munc18c in ECs.
As vesicle trafficking proteins participate in the secretion of granule contents, we evaluated the consequences of disrupting PP2B-Aa-Munc18c for the regulation of agonist-induced VWF secretion in HUVECs. HUVECs pretreated with DMSO or control scrambled peptide and challenged with histamine or thrombin showed increased secretion of VWF into the medium (Fig. 3A,B) . However, as compared with HUVECs treated with the vehicle DMSO control or the scrambled myristylated peptide, addition of 10 lM PP2B peptide resulted in a moderate but significant reduction in histamine-induced (5 lM and 10 lM) and thrombin-induced (0.05 U mL
À1
) VWF secretion (Fig. 3A,B) . VWF secretion induced by thrombin at a higher dose (0.5 U mL À1 ) was not significantly affected by the PP2B peptide. The inhibitory effect of the PP2B peptide on histamine-induced VWF secretion was comparable to that of H 2 O 2 , a known VWF secretion inhibitor (Fig. 4A ). H 2 O 2 blocks VWF secretion by inhibiting NSF, a protein that is important for membrane fusion in exocytosis [18] . However, the PP2B peptide was not effective in blocking VWF secretion if it was added after histamine stimulation (Fig. 4B) . These studies indicate that PP2B-Aa-Munc18c supports low-dose agonist-induced exocytosis of VWF. PP2B peptide-based disruption of PP2B-Aa-Munc18c did not alter serine phosphorylation of Munc18c in response to histamine and thrombin (data not shown), suggesting that the function of this protein complex is unlikely to be a direct regulator of Munc18c phosphorylation. Structural studies on PP2B have indicated that the putative active site of this enzyme contains a binuclear metal center that is important for the phosphatase activity [19, 20] . Asp121 and Arg122 lie within close vicinity of the binuclear metal center in the active site [16] , and mutagenesis of Arg122 decreased PP2B activity [21] . As amino acids 121-130 of PP2B-Aa are engaged in an interaction with Munc18c, it is possible that the local phosphatase activity of PP2B in this protein complex may be perturbed, such that the complex may not directly regulate the phosphorylation of Munc18c. The increased serine phosphorylation of Munc18c that was noticed in ECs treated with the PP2B inhibitor (cyclosporine) [14] may be attributable to an indirect effect of global PP2B on other signaling proteins that can influence Munc18c phosphorylation. There is precedence for this, in that Munc18c has been shown to interact with protein kinase Cf [22] , WNK1 (an unusual novel Ser/Thr kinase called with no K (lysine) 1) [23] , cyclin-dependent kinase 5 [24] , protein tyrosine phosphatase 1B [25] , and the scaffolding protein Doc2b [26] . Myristylated PP2B peptide-based disruption of PP2B-Aa-Munc18c, prior to agonist stimulation in ECs, may locally provide a pool of free PP2B-Aa to suppress the phosphorylation of one or more proteins in the secretory machinery (SNARE, accessory proteins, and cytoskeletal proteins), which support the secretion of granule contents and thereby decrease agonist-induced VWF secretion. In line with this argument, we noticed that the PP2B peptide moderately decreased histamine-induced Ser95 phosphorylation of SNAP-23 (Fig. 4C,D) , which correlated with the decreased VWF secretion. Ser95 phosphorylation of SNAP-23 regulates the secretion of mast cells and platelets [17, 27] . Conversely, pharmacologic inhibition of global PP2B activity and genetic deletion of PP2B-Aa or PP2B-Ab resulted in enhanced VWF exocytosis [14] . Exocytosis of VWF in response to the inflammatory mediator histamine was more sensitive than that induced by thrombin to changes induced by the disruption of PP2B-Aa-Munc18c, suggesting a prominent role for PP2B in histamine-induced secretion. Indeed, in HUVECs, histamine, unlike thrombin, provoked a large increase in intracellular Ca 2+ via STIM1 and Orai1 and the activated PP2B/nuclear factor of activated T cells pathway [28, 29] . Disruption of selected phosphatase complexes such as PP2A-Raf, PP2A-IKK and PP2A-Akt-bArr2 by small molecules to achieve therapeutic value in inflammation, proliferation and mood disorders is attracting considerable interest [30] . Our approach to disrupting the phosphatase complex by using the PP2B peptide has limitations, as these peptides could also interact with other protein complexes that bear similar sequences. Nevertheless, these studies suggest that PP2B-Aa-Munc18c could potentially serve as a target for the treatment of certain thrombotic and inflammatory disorders.
In conclusion, using ECs as a secretory system, we have identified an essential role for PP2B-Aa-Munc18c in VWF secretion. This was achieved by generating a reagent that selectively targets the unique interaction domain of PP2B-A. As PP2B-Aa and Munc18 proteins are ubiquitous, and secretion occurs in multiple cell types, it is likely that PP2B-Aa-Munc18c may also regulate granule exocytosis in secretory systems other than ECs.
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